-
1 Comment
Heilongjiang ZBD Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 22.4% above its 200 day moving average.
From a valuation standpoint, the stock is 60.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.8.
Heilongjiang ZBD Pharmaceutical Co., Ltd's total revenue sank by 35.8% to $412M since the same quarter in the previous year.
Its net income has dropped by 44.2% to $56M since the same quarter in the previous year.
Finally, its free cash flow fell by 119.2% to $-218M since the same quarter in the previous year.
Based on the above factors, Heilongjiang ZBD Pharmaceutical Co., Ltd gets an overall score of 2/5.
| Exchange | SHG |
|---|---|
| CurrencyCode | CNY |
| ISIN | CNE100002219 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Beta | 0.25 |
|---|---|
| Market Cap | 10B |
| PE Ratio | 15.65 |
| Target Price | None |
| Dividend Yield | None |
Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthopedics, tumors, digestive system, anti-infection, mental nerve, genitourinary, and other disease fields. The company was founded in 1996 and is based in Hulin, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 603567.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
